If at first... pharma’s most drawn-out development timelines revealed
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
Prometheus takes on Pfizer in inflammatory bowel diseases
It is make or break time for the smaller group’s TL1A inhibitor PRA023.
Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
